IDEXX Laboratories, Inc. (IDXX) Reaches $176.42 High on Jan, 16; Sectoral Asset Management Boosted Portola Pharmaceuticals (PTLA) Holding

January 16, 2018 - By Vivian Currie

The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) reached all time high today, Jan, 16 and still has $183.48 target or 4.00% above today’s $176.42 share price. This indicates more upside for the $15.39B company. This technical setup was reported by Barchart.com. If the $183.48 PT is reached, the company will be worth $615.48M more. The stock increased 1.84% or $3.18 during the last trading session, reaching $176.42. About 170,013 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since January 16, 2017 and is uptrending. It has outperformed by 66.60% the S&P500.

Sectoral Asset Management Inc increased Portola Pharmaceuticals (PTLA) stake by 19.96% reported in 2017Q3 SEC filing. Sectoral Asset Management Inc acquired 84,271 shares as Portola Pharmaceuticals (PTLA)’s stock rose 22.73%. The Sectoral Asset Management Inc holds 506,414 shares with $27.36M value, up from 422,143 last quarter. Portola Pharmaceuticals now has $3.36 billion valuation. The stock decreased 2.07% or $1.09 during the last trading session, reaching $51.53. About 267,832 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since January 16, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Sectoral Asset Management Inc decreased Regeneron Pharmaceuticals (NASDAQ:REGN) stake by 29,981 shares to 32,917 valued at $14.72M in 2017Q3. It also reduced Acadia Pharmaceuticals (NASDAQ:ACAD) stake by 276,417 shares and now owns 822,392 shares. Integra Lifescience (NASDAQ:IART) was reduced too.

Investors sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. It increased, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Voya Mngmt Ltd Com has 0.03% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Moreover, D E Shaw Company Inc has 0.09% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Us National Bank De reported 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Dimensional Fund Advsrs Lp reported 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Fiera Corporation has invested 0.02% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). State Street Corporation holds 2.40M shares or 0.01% of its portfolio. Ny State Common Retirement Fund reported 60,180 shares. Omega Advsr Incorporated stated it has 50,000 shares. Kazazian Asset Ltd Llc holds 12,241 shares. Dekabank Deutsche Girozentrale stated it has 28,400 shares or 0.01% of all its holdings. State Board Of Administration Of Florida Retirement Sys stated it has 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Brown Advisory Inc holds 8,813 shares or 0% of its portfolio. Vanguard Group holds 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 5.24M shares. Focused Wealth Incorporated holds 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 125 shares. Credit Agricole S A invested in 37,500 shares.

Since December 15, 2017, it had 0 insider buys, and 1 sale for $563,950 activity. Shares for $563,950 were sold by Wolff Henry Ward on Friday, December 15.

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 32 analyst reports since August 5, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $7000 target in Wednesday, August 9 report. Oppenheimer maintained the stock with “Buy” rating in Wednesday, December 13 report. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Monday, June 26 with “Buy” rating. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Oppenheimer on Friday, August 4. The firm has “Hold” rating given on Thursday, August 10 by Credit Suisse. Morgan Stanley maintained the shares of PTLA in report on Friday, October 6 with “Overweight” rating. The company was initiated on Friday, December 1 by Goldman Sachs. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 5 report. Credit Suisse maintained the shares of PTLA in report on Wednesday, September 20 with “Buy” rating. The company was downgraded on Tuesday, May 31 by Credit Suisse.

Among 10 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 6 have Buy rating, 2 Sell and 2 Hold. Therefore 60% are positive. IDEXX Laboratories had 23 analyst reports since July 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Buy” rating in Thursday, October 5 report. The firm earned “Buy” rating on Monday, August 21 by Stifel Nicolaus. The firm earned “Buy” rating on Wednesday, August 23 by Bank of America. The rating was reinitiated by Bank of America with “Neutral” on Thursday, September 29. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) has “Neutral” rating given on Friday, April 1 by CL King. The rating was downgraded by Raymond James on Friday, August 28 to “Market Perform”. C.L. King upgraded the shares of IDXX in report on Friday, July 28 to “Buy” rating. The firm has “Buy” rating given on Thursday, July 23 by Canaccord Genuity. As per Monday, October 23, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, June 13 by Canaccord Genuity.

Since August 8, 2017, it had 0 buys, and 6 sales for $26.12 million activity. Another trade for 5,156 shares valued at $790,342 was sold by HENDERSON REBECCA M. AYERS JONATHAN W sold $2.63M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Wednesday, August 9.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, makes, and distributes services and products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company has market cap of $15.39 billion. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other divisions. It has a 57.32 P/E ratio. The firm provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on February, 1. They expect $0.73 earnings per share, up 25.86% or $0.15 from last year’s $0.58 per share. IDXX’s profit will be $63.67 million for 60.42 P/E if the $0.73 EPS becomes a reality. After $0.79 actual earnings per share reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -7.59% negative EPS growth.

Investors sentiment decreased to 0.86 in 2017 Q3. Its down 0.33, from 1.19 in 2017Q2. It fall, as 39 investors sold IDEXX Laboratories, Inc. shares while 196 reduced holdings. 55 funds opened positions while 146 raised stakes. 87.85 million shares or 15.07% more from 76.34 million shares in 2017Q2 were reported. Chevy Chase Tru Holdg has 76,276 shares. Amer Gru Inc accumulated 30,951 shares. 14,735 were reported by Suntrust Banks. Maverick Cap Ltd accumulated 32,420 shares. Nationwide Fund Advisors holds 0.11% in IDEXX Laboratories, Inc. (NASDAQ:IDXX) or 177,087 shares. Df Dent And has invested 0.49% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Moreover, Long Road Counsel Ltd has 1.24% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Welch Forbes Ltd reported 192,996 shares. Oregon Public Employees Retirement Fund has invested 0.09% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Evercore Wealth Management Ltd Com accumulated 63,462 shares or 0.38% of the stock. Zacks Inv holds 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 6,016 shares. Huntington Bank, a Ohio-based fund reported 1,490 shares. Gsa Capital Ptnrs Llp invested in 0.11% or 10,727 shares. Gotham Asset Mngmt Ltd Com has invested 0.01% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Meeder Asset Mngmt has invested 0.03% in IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: